Modus Therapeutics Holding AB (99Z)

Overview

Modus Therapeutics Holding AB (publ) is a pioneering biotechnology firm based in Stockholm, Sweden, focusing on the development of novel treatments specifically targeting sepsis and septic shock. Founded in 2011, the company aims to fill a critical gap in the healthcare industry by creating solutions for these severe, life-threatening conditions that result from systemic inflammation. With its dedication to research and development, Modus Therapeutics is at the forefront of addressing the urgent need for effective therapies in the realm of infectious diseases and systemic inflammatory responses.

Products and Services

• Sevuparin

  The flagship product of Modus Therapeutics, Sevuparin, stands as a significant advancement in the treatment of sepsis and septic shock, along with other systemic inflammatory conditions. Engineered as a lipopolysaccharide, Sevuparin is designed to combat the severe complications arising from these conditions by targeting and neutralizing the underlying causes of inflammation and coagulation disorders. Currently in Phase Ib clinical study, Sevuparin embodies the company's commitment to saving lives by addressing one of the most challenging emergencies in clinical medicine.